Vensana Capital

Vensana Capital, established in 2019 and headquartered in Minneapolis, Minnesota, is a venture capital firm specializing in healthcare and related technologies. It invests in innovative medical technology, digital health, and life science sectors, with a focus on breakthrough solutions. The firm manages multiple funds, including Vensana Capital I and II, and is registered as an Investment Adviser.

Greg Banker

Partner

Justin Klein

Managing Partner

Steve Schwen

CFO

Amrinder Singh

Partner

Amrinder Singh

Partner

24 past transactions

Evident Vascular

Series B in 2025
Evident Vascular offers an advanced IVUS platform that leverages Artificial Intelligence to deliver superior Vascular.

Alleviant Medical

Venture Round in 2025
Alleviant Medical, Inc. is a medical device company focused on developing therapies for congestive heart failure. Founded in 2017 and headquartered in Austin, Texas, the company offers a proprietary transcatheter device designed to provide minimally invasive treatment for heart failure. This innovative technology aims to relieve pressure buildup in the left atrium, which can lead to organ failures, thereby alleviating symptoms of heart failure. By improving patients' quality of life and reducing hospital admissions due to heart failure exacerbations, Alleviant Medical addresses the needs of over 6 million Americans suffering from this condition.

Okami Medical

Venture Round in 2024
Okami Medical, Inc. is a manufacturer of medical devices specializing in the occlusion of peripheral vessels, primarily through its innovative LOw-profile Braided Occluder (LOBO) system. This device provides interventional physicians with a single solution for occluding various arterial targets, eliminating the need for multiple embolic devices. The LOBO incorporates proprietary HDBRAID technology, which features a unique pore structure that effectively reduces blood flow and accelerates vessel closure. Founded in 2011 and headquartered in Aliso Viejo, California, Okami Medical was established to meet the evolving needs of patients and healthcare providers by developing versatile and intuitive devices that ensure rapid and reliable vessel occlusion under diverse conditions.

iVEAcare

Series A in 2024
iVEAcare focuses on developing innovative neuromodulation therapies aimed at addressing unmet clinical needs in the treatment of chronic diseases. The company creates advanced devices and software that provide targeted electrical stimulation to specific regions of the brain or spinal cord. This technology allows medical professionals to design therapies that are not only more effective but also less invasive than conventional treatments, thereby expanding access to a broader patient population.

Elucent Medical

Series C in 2024
Elucent Medical LLC is focused on improving breast cancer treatment processes through innovative technology. Founded in 2014 and headquartered in Brookfield, Wisconsin, the company has developed a wireless marker tag and detection system that enhances the surgical excision of breast abnormalities. This advanced surgical navigation technology allows for real-time data processing, enabling surgeons to accurately locate tumor margins and enhance the precision of procedures. By eliminating the need for metal clips, Elucent Medical's solutions aim to simplify breast cancer treatment, making it more accessible and affordable while helping to preserve patients' breasts during surgery. The company's offerings benefit both healthcare providers and patients by improving overall surgical outcomes.

Evident Vascular

Series A in 2023
Evident Vascular offers an advanced IVUS platform that leverages Artificial Intelligence to deliver superior Vascular.

SpyGlass Pharma

Series C in 2023
Spyglass Pharma specializes in developing innovative treatments for chronic ophthalmic diseases, leveraging advanced technology to enhance patient care and vision. The company focuses on creating ophthalmic devices and a drug delivery platform that addresses unmet needs in areas such as cataracts and lens replacement surgeries. Its delivery system is designed to be implanted alongside intraocular lenses during standard cataract procedures, allowing surgeons to administer multi-year therapies for chronic conditions. This approach aims to improve the accessibility and affordability of quality eye treatments for patients, ensuring better outcomes in ophthalmic care.

Artelon

Series B in 2023
Artelon focuses on the development of innovative synthetic materials for orthopedic soft tissue reconstruction, particularly in tendon and ligament repair. The company provides kinematic reinforcement solutions that enhance the stability and motion of joints, facilitating effective recovery from joint instability. Through its specialized bio-textiles, Artelon aims to assist surgeons in restoring joint strength and function, ultimately improving patient outcomes in orthopedic procedures.

Relievant Medsystems

Venture Round in 2023
Relievant Medsystems, Inc. is a medical device company focused on developing minimally invasive treatments for chronic axial low back pain. The company has created the Intracept procedure, which specifically targets the basivertebral nerve to alleviate chronic vertebrogenic low back pain. By delivering targeted energy into the spine, the Intracept System effectively blocks the transmission of pain signals, providing patients with a low-risk therapeutic option. Founded in 2004, Relievant is headquartered in Minneapolis, Minnesota, with additional operations in Sunnyvale, California.

Alleviant Medical

Venture Round in 2023
Alleviant Medical, Inc. is a medical device company focused on developing therapies for congestive heart failure. Founded in 2017 and headquartered in Austin, Texas, the company offers a proprietary transcatheter device designed to provide minimally invasive treatment for heart failure. This innovative technology aims to relieve pressure buildup in the left atrium, which can lead to organ failures, thereby alleviating symptoms of heart failure. By improving patients' quality of life and reducing hospital admissions due to heart failure exacerbations, Alleviant Medical addresses the needs of over 6 million Americans suffering from this condition.

Volta Medical

Series B in 2023
Volta Medical is a technology company based in Marseille, France, founded in 2016, that specializes in developing artificial intelligence software for interventional cardiology. The company focuses on aiding cardiologists in the treatment of atrial fibrillation, the most common cardiac arrhythmia. Volta Medical's flagship product utilizes advanced AI algorithms to analyze electrograms and guide mapping catheters during cardiac procedures. This software assists interventional cardiologists by providing real-time insights and step-by-step guidance, enhancing their ability to make informed decisions during patient-specific medical interventions. The company aims to improve the effectiveness of cardiac procedures and the overall management of atrial fibrillation through innovative technological solutions.

Nyra Medical

Series A in 2022
Nyra Medical is focused on creating innovative transcatheter heart valve repair technology aimed at treating mitral regurgitation. The company's device is designed to address the leaflets of heart valves while preserving the natural geometry of the mitral valve. By utilizing a proprietary implant, Nyra Medical's technology enables patients to achieve consistent correction of valve regurgitation, improving their overall heart function.

Cleerly

Series C in 2022
Cleerly is a healthcare company focused on improving the prevention of heart attacks through innovative digital care pathways. It aims to establish a new standard for coronary artery disease by combining advanced clinical science with cutting-edge artificial intelligence. Cleerly's platform offers a non-invasive approach that quantifies and characterizes plaque buildup in coronary arteries, enhancing the understanding of cardiovascular health. By providing actionable clinical insights, the company enables healthcare providers to better identify at-risk patients and implement early treatment strategies. Ultimately, Cleerly's data-driven solutions aspire to deliver significant value to the healthcare system while improving heart health outcomes for individuals susceptible to heart attacks.

Moxe

Series B in 2022
Moxe Health specializes in facilitating the bi-directional exchange of clinical data between health plans and provider systems through its innovative clinical data integration platform. The company offers a range of services including risk adjustment, claims denial management, clinical summaries, administrative notifications, and care gap management. By creating an interactive network, Moxe ensures that health systems and health plans can share medical records and crucial patient insights quickly and efficiently, without disrupting clinicians' existing workflows. The platform supports the transition to value-based care by providing automated solutions that enhance access to essential information, allowing organizations to leverage their investments in population health and analytics effectively. Moxe's commitment to neutrality in data connectivity further enhances its value proposition in the healthcare industry.

Apella

Series A in 2021
Apella is an artificial intelligence startup focused on enhancing surgical procedures through advanced healthcare technology. Founded in 2019 and headquartered in San Francisco, California, the company develops systems that utilize AI, computer vision, and modern communication to digitize operating rooms. By collecting data from these environments via sensors, Apella analyzes the information to provide insights that can improve surgical quality, streamline operations, and aid in training and real-time decision-making for medical staff. Its innovative approach aims to elevate surgery outcomes and optimize the overall efficiency of healthcare delivery.

Cleerly

Series B in 2021
Cleerly is a healthcare company focused on improving the prevention of heart attacks through innovative digital care pathways. It aims to establish a new standard for coronary artery disease by combining advanced clinical science with cutting-edge artificial intelligence. Cleerly's platform offers a non-invasive approach that quantifies and characterizes plaque buildup in coronary arteries, enhancing the understanding of cardiovascular health. By providing actionable clinical insights, the company enables healthcare providers to better identify at-risk patients and implement early treatment strategies. Ultimately, Cleerly's data-driven solutions aspire to deliver significant value to the healthcare system while improving heart health outcomes for individuals susceptible to heart attacks.

GPB Scientific

Venture Round in 2021
GPB Scientific, LLC is a biotechnology company based in Richmond, Virginia, that specializes in developing a liquid biopsy platform aimed at isolating viable circulating tumor cells from blood samples. The company offers a desktop fluidic system that processes whole blood through a disposable microchip, effectively separating and enriching rare tumor cells while removing red blood cells and normal white blood cells. GPB Scientific markets its innovative technology to life sciences companies and research institutions, supported by a substantial portfolio of patents related to microchip technology for cell capture and enrichment. Established in 2002, GPB Scientific continues to advance its contributions to cancer diagnostics and research.

Personal Genome Diagnostics

Series C in 2021
Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.

Spyglass Ophthalmics

Series B in 2021
Spyglass Ophthalmics, Inc. is a company focused on developing ophthalmic therapeutic devices aimed at enhancing vision and eye care for patients. Founded in 2019 and based in Mission Viejo, California, Spyglass addresses unmet needs in areas such as cataract treatment, lens replacement, and other chronic ophthalmic conditions. By creating innovative devices, the company seeks to provide patients with quality eye treatment that is also affordable.

Relievant Medsystems

Venture Round in 2020
Relievant Medsystems, Inc. is a medical device company focused on developing minimally invasive treatments for chronic axial low back pain. The company has created the Intracept procedure, which specifically targets the basivertebral nerve to alleviate chronic vertebrogenic low back pain. By delivering targeted energy into the spine, the Intracept System effectively blocks the transmission of pain signals, providing patients with a low-risk therapeutic option. Founded in 2004, Relievant is headquartered in Minneapolis, Minnesota, with additional operations in Sunnyvale, California.

CVRx

Venture Round in 2020
CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.

GPB Scientific

Venture Round in 2020
GPB Scientific, LLC is a biotechnology company based in Richmond, Virginia, that specializes in developing a liquid biopsy platform aimed at isolating viable circulating tumor cells from blood samples. The company offers a desktop fluidic system that processes whole blood through a disposable microchip, effectively separating and enriching rare tumor cells while removing red blood cells and normal white blood cells. GPB Scientific markets its innovative technology to life sciences companies and research institutions, supported by a substantial portfolio of patents related to microchip technology for cell capture and enrichment. Established in 2002, GPB Scientific continues to advance its contributions to cancer diagnostics and research.

Intact Vascular

Series D in 2019
Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.

Vesper Medical

Venture Round in 2019
Vesper Medical, Inc. is a medical device company established in 2016 and based in Wayne, Pennsylvania. The company focuses on developing minimally invasive peripheral vascular products specifically designed for treating deep venous disease. Its flagship offering, the Vesper DUO Venous Stent System, features a unique combination of strength and flexibility that addresses the complex anatomical challenges of venous stenting, particularly in the iliac and femoral veins. Vesper Medical aims to provide safe, effective, and user-friendly solutions for both patients and healthcare providers, enhancing the treatment of deep venous conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.